23 completed, 9 terminated, 2 withdrawn, 1 recruiting. 36 Phase 3, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 36 | Completed 23, Terminated 9, Withdrawn 2, Recruiting 1, Unknown 1 |
| Phase 2 | 2 | Completed 2 |
Follow ziprasidone: new trials by email Literature Review of ziprasidone trials Research Report on ziprasidone
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Lumateperone for the Improvement of Apathy in Patients With Psychotic Symptoms. Lumateperone 42 mg, Risperidone 2 mg - Apathy, Schizophrenia | Phase 3 | Recruiting | Louisiana State University Health Sciences Center Shreveport | 80 | 2024-06-01 | 2024-07-01 |
| Extension Study Evaluating The Safety And Tolerability Of Flexible Doses Of Oral Ziprasidone In Children And Adolescents With Bipolar I Disorder Ziprasidone, Placebo - Bipolar Disorder | Phase 3 | Terminated | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | 23 | 2018-12-21 | 2021-06-16 |
| Pharmacovigilance in Gerontopsychiatric Patients Phenobarbital, Phenytoin, Carbamazepine - Dementia, Depression | Phase 3 | Terminated | Hannover Medical School | 407 | 2015-01-01 | 2018-02-28 |
| Efficacy and Safety Trial of Flexible Doses of Oral Ziprasidone in Children and Adolescents With Bipolar I Disorder placebo oral capsules, ziprasidone oral capsules - Bipolar Disorder | Phase 3 | Terminated | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | 171 | 2014-05-23 | 2021-06-16 |
| Clinical Trial to Evaluate the Efficacy of Treatment vs Discontinuation in a First Episode of Non-affective Psychosis Discontinuation antipsychotic treatment, Antipsychotic treatment - Psychosis Nos/Other | Phase 3 | Unknown | Fundación Pública Andaluza Progreso y Salud | 104 | 2012-11-01 | 2014-12-05 |
| The Modifying the Impact of ICU-Associated Neurological Dysfunction-USA (MIND-USA) Study Haloperidol, Ziprasidone, Placebo - Delirium, Impaired Cognition | Phase 3 | Completed | Vanderbilt University Medical Center | 566 | 2011-12-14 | 2019-11-18 |
| Safety And Tolerability Of Flexible Doses Of Oral Ziprasidone In Children And Adolescents With Bipolar I Disorder (Manic Or Mixed) ziprasidone oral capsules - Bipolar Disorder | Phase 3 | Withdrawn | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | 2010-07-01 | 2021-02-21 | |
| One-Year Trial of Oral Ziprasidone in Bipolar Patients With Metabolic Syndrome Ziprasidone HCL (oral) - Bipolar Disorder | Phase 3 | Terminated | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | 13 | 2010-07-01 | 2021-03-03 |
| Safety And Efficacy Of Ziprasidone In Children And Adolescents With Bipolar I Disorder (Manic Or Mixed) (Protocol A1281196) Placebo, Ziprasidone Oral Capsules - Bipolar Disorder | Phase 3 | Withdrawn | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | 2010-06-01 | 2021-02-21 | |
| A Randomized, Open-Label, Multi-Center Study To Evaluate The Efficacy And Safety Of Intramuscular Ziprasidone In Patients With Agitation Intramuscular ziprasidone mesylate, Intramuscular haloperidol - Schizophrenia | Phase 3 | Completed | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | 376 | 2008-09-01 | 2021-03-03 |
| Adjunctive Ziprasidone in the Treatment of Bipolar I Depression Ziprasidone, Placebo - Bipolar Disorder, Depression, Bipolar | Phase 3 | Completed | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | 298 | 2007-10-01 | 2021-03-10 |
| Switch Study of Existing Atypical Antipsychotics to Bifeprunox Aripiprazole, Olanzapine, Risperidone - Schizophrenia and Schizoaffective Disorder | Phase 3 | Completed | Solvay Pharmaceuticals | 286 | 2006-12-01 | 2008-05-21 |
| Safety And Tolerability Of Ziprasidone In Adolescents With Schizophrenia Ziprasidone oral capsules - Schizophrenia | Phase 3 | Terminated | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | 221 | 2006-06-01 | 2021-03-03 |
| Open-label Ziprasidone Study for Psychosis Treatment in Adolescents Ziprasidone - Schizophreniform Disorder, Schizoaffective Disorder | Phase 3 | Completed | New York State Psychiatric Institute | 8 | 2006-05-01 | 2017-01-13 |
| 3-week Study to Evaluate Efficacy and Safety of Ziprasidone With Either Lithium or Divalproex in Acutely Manic Subjects Placebo, Ziprasidone - Bipolar Disorder | Phase 3 | Completed | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | 680 | 2006-04-01 | 2021-03-29 |
| Safety And Efficacy Of Ziprasidone In Adolescents With Schizophrenia placebo, Ziprasidone oral capsules - Schizophrenia | Phase 3 | Terminated | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | 284 | 2006-04-01 | 2021-03-25 |
| Safety and Tolerability of Ziprasidone in Children and Adolescents With Bipolar I Disorder (Manic or Mixed) Ziprasidone oral capsules - Bipolar Disorder | Phase 3 | Completed | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | 169 | 2006-03-01 | 2021-03-25 |
| A Six-week Flexible Dose Study Evaluating the Efficacy and Safety of Geodon in Patients With Bipolar I Depression. Placebo, Geodon (Ziprasidone) - Bipolar Disorder | Phase 3 | Completed | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | 392 | 2006-02-01 | 2021-03-29 |
| Estimating and Reducing the Cardiovascular Risk of Patients With Schizophrenia Drugs From Lipid Measures and Ischemic Electrocardiographic Changes aripiprazole (Abilify), ziprasidone (Geodon) - Schizophrenia, Schizoaffective Disorder | Phase 3 | Terminated | Northwestern University | 48 | 2006-01-01 | 2025-10-02 |
| High-Dose Oral Ziprasidone Versus Conventional Dosing in Participants With Residual Schizophrenia Symptoms Ziprasidone 80-160 mg/d, Placebo, Ziprasidone 160 mg/d - Schizophrenia | Phase 3 | Completed | Donald C. Goff, MD | 131 | 2006-01-01 | 2017-06-06 |
Showing 20 of 36. Sign in to see all of them.
Schizophrenia (19) · Bipolar Disorder (14) · Psychotic Disorders (8) · Mental Disorders (3) · Metabolic Syndrome (2) · Anxiety Disorders (1) · Cognition Disorders (1) · Delirium (1) · Dementia (1) · Depression (1) · Depressive Disorder, Major (1) · Diabetes Mellitus (1) · Lethargy (1) · Mania (1) · Mood Disorders (1)
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (24) · Donald C. Goff, MD (1) · Duke University (1) · Fundación Pública Andaluza Progreso y Salud (1) · Hannover Medical School (1) · Louisiana State University Health Sciences Center Shreveport (1) · Manhattan Psychiatric Center (1) · New York State Psychiatric Institute (1) · Northwestern University (1) · Solvay Pharmaceuticals (1) · University of Pittsburgh (1) · Vanda Pharmaceuticals (1) · Vanderbilt University Medical Center (1)
United States (21) · India (6) · Italy (5) · France (3) · Russia (3) · Spain (3) · Ukraine (3) · Canada (2) · China (2) · Colombia (2) · Costa Rica (2) · Germany (2) · Malaysia (2) · Peru (2) · Singapore (2)
Adel Elsheshai, MD (1) · Donald Goff, M.D. (1) · E. Wesley Ely, MD, MPH (1) · Frederick Cassidy, MD (1) · George Simpson, MD (1) · Helge Frieling, Prof., MD (1) · Jean-Pierre Lindenmayer, M.D. (1) · K.N. Roy Chengappa, MD (1) · Lawrence A Maayan, MD (1) · Miguel Ruiz Veguilla, MD, PhD (1) · Ranga Krishnan, MD (1) · Saurabh Kaushik, M.D. (1) · Shawn McNeil, MD (1)
PMID 23609405, PMID 24111980, PMID 24111983, PMID 35394365, PMID 18312045, PMID 19542525, PMID 19573479, PMID 19818257, PMID 20122373, PMID 21672493, PMID 21796719, PMID 23218157, PMID 23218158, PMID 23422376, PMID 25012414, PMID 25385032, PMID 30346242, PMID 36282771, PMID 38252439, PMID 38701817, PMID 40198074, PMID 41739187